Elevance Health reported its financial results for the first quarter of 2025, surpassing analyst expectations. The company posted an adjusted earnings per share (EPS) of $11.97, beating the estimated $11.38. Revenue reached $48.77 billion, exceeding the forecasted $46.29 billion and representing a 15.36% year-over-year increase. The Carelon segment experienced strong growth with a 38% rise in revenue, driven by acquisitions and higher product volume. Despite industry-wide pressures from elevated cost trends, Elevance Health reported a net profit of $2.2 billion for the quarter. The company also noted lower-than-expected medical costs contributing to its profit beat. These results reflect robust operational performance and growth across its business segments.